7th Apr 2022 07:00
7 April 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Purchase and Sale of Shares and PDMR Shareholdings
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces the following Director and PDMR share dealings.
On 5 April 2022, Nick Roberts, CFO of Diaceutics, purchased 39,179 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.015 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 39,179 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital.
On 6 April 2022, Deborah Davis, the Chair of Diaceutics, purchased 20,000 Ordinary Shares at an average price of £1.0125 pence per share. As a result of the purchase, Deborah's shareholding is 64,800 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.
On 6 April 2022, Charles Hindson, Non-Executive Director of Diaceutics, purchased 20,000 Ordinary Shares at a price of £1.01 pence per share. As a result of the purchase, Charles' shareholding is 63,500 Ordinary Shares, representing approximately 0.08 % of the Company's issued share capital.
Across 5 and 6 April 2022, Philip White, a PDMR, sold 200,000 Ordinary Shares at an average price of £0.989 pence per Ordinary Share. As a result of Philip's sale, the beneficial holding of Philip White and his connected parties in the Company is 1,406,389 Ordinary Shares, representing 1.67 % of the Company's issued share capital.
Enquiries:
Diaceutics PLC |
|
Nick Roberts, Chief Financial Officer | Via Alma PR |
|
|
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison |
|
Stewart Wallace |
|
Nick Adams |
|
|
|
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | |
Kieran Breheny |
|
Matthew Young |
|
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Nick Roberts | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | CFO | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Purchase | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
£1.015 | 39,179 | ||||||
d. | Date of the transaction | 5 April 2022 | |||||
e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Deborah Davis | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chair | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Purchase | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
£1.01 £1.02 | 15,000 5,000 | ||||||
d. | Date of the transaction | 6 April 2022 | |||||
e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Charles Hindson | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Non-Executive Director | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Purchase | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
£1.01 | 20,000 | ||||||
d. | Date of the transaction | 6 April 2022 | |||||
e. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Philip White | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Sale | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
£1.01 £0.98 | 60,000 140,000 | ||||||
| |||||||
e. | Date of the transaction | 5 & 6 April 2022 | |||||
f. | Place of the transaction | AIM Market of the London Stock Exchange | |||||
Related Shares:
Diaceutics